Edward Miller's most recent trade in Kalaris Therapeutics Inc. was a trade of 106 Common Stock done at an average price of $10.1 . Disclosure was reported to the exchange on Feb. 21, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 10.08 per share. | 21 Feb 2025 | 106 | 6,517 | - | 10.1 | 1,068 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 9.45 per share. | 23 Jan 2025 | 47 | 6,628 | - | 9.4 | 444 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 23 Jan 2025 | 5 | 6,623 | - | 10 | 50 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.44 per share. | 10 Jan 2025 | 409 | 153,541 | - | 0.4 | 180 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Dec 2024 | 57,549 | 346,348 | - | 0 | Common Stock | |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Dec 2024 | 57,549 | 153,950 | - | 0 | Common Stock | |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.55 per share. | 19 Nov 2024 | 432 | 211,499 | - | 0.5 | 237 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.86 per share. | 05 Nov 2024 | 2,272 | 211,931 | - | 0.9 | 1,965 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.77 per share. | 21 Oct 2024 | 766 | 214,203 | - | 0.8 | 588 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 21 Oct 2024 | 635 | 214,969 | - | 0.8 | 495 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.81 per share. | 03 Oct 2024 | 377 | 215,604 | - | 0.8 | 307 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.76 per share. | 19 Aug 2024 | 422 | 215,981 | - | 0.8 | 321 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.73 per share. | 05 Aug 2024 | 2,323 | 216,403 | - | 0.7 | 1,707 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.74 per share. | 19 Jul 2024 | 757 | 218,726 | - | 0.7 | 560 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.75 per share. | 19 Jul 2024 | 634 | 219,483 | - | 0.8 | 476 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.72 per share. | 02 Jul 2024 | 379 | 220,117 | - | 0.7 | 273 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.75 per share. | 17 May 2024 | 420 | 220,496 | - | 0.8 | 315 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.80 per share. | 03 May 2024 | 2,311 | 220,916 | - | 0.8 | 1,840 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.75 per share. | 19 Apr 2024 | 757 | 223,227 | - | 0.8 | 568 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.75 per share. | 19 Apr 2024 | 626 | 223,984 | - | 0.8 | 470 | Common Stock |
NextPlat Corp | John Edward Miller | Director | Purchase of securities on an exchange or from another person at price $ 7150.00 per share. | 16 Apr 2024 | 5,000 | 28,000 (23%) | 4% | 7150 | 35,750,000 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.77 per share. | 02 Apr 2024 | 368 | 224,610 | - | 0.8 | 284 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.70 per share. | 20 Feb 2024 | 385 | 224,978 | - | 0.7 | 268 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.67 per share. | 05 Feb 2024 | 8,869 | 225,363 | - | 0.7 | 5,942 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.67 per share. | 23 Jan 2024 | 1,302 | 234,232 | - | 0.7 | 873 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 0.64 per share. | 04 Jan 2024 | 424 | 235,534 | - | 0.6 | 271 | Common Stock |
NextPlat Corp | John Edward Miller | Director | 31 Dec 2023 | 20,000 | 20,000 | - | - | Stock Option | ||
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 162,500 | 497,844 | - | - | Stock Option (Right to Buy) | |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 87,500 | 235,958 | - | 0 | Common Stock | |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Jan 2023 | 98,346 | 288,799 | - | 0 | Common Stock | |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Jan 2023 | 98,346 | 151,031 | - | 0 | Common Stock | |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 5.08 per share. | 19 Jan 2023 | 2,032 | 148,999 | - | 5.1 | 10,318 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 5.14 per share. | 19 Jan 2023 | 541 | 148,458 | - | 5.1 | 2,783 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 8.91 per share. | 14 Nov 2022 | 2,358 | 190,453 | - | 8.9 | 21,018 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 9.36 per share. | 20 Oct 2022 | 553 | 249,377 | - | 9.4 | 5,176 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2022 | 15,000 | 249,930 | - | 0 | Common Stock | |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 14,000 | 234,930 | - | 0 | Common Stock | |
NextPlat Corp | John Edward Miller | Director | Purchase of securities on an exchange or from another person at price $ 9775.20 per share. | 28 Jan 2022 | 3,000 | 23,000 (18%) | 2% | 9775.2 | 29,325,600 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 56,744 | 56,744 | - | - | Stock Option (Right to Buy) | |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 23,256 | 217,307 | - | 0 | Common Stock | |
NextPlat Corp | John Edward Miller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2021 | 20,000 | 20,000 (16%) | 16% | 0 | Common Stock, par value $0.0001 | |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 38.58 per share. | 01 Mar 2021 | 3,800 | 195,011 | - | 38.6 | 146,592 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Sale of securities on an exchange or to another person at price $ 39.14 per share. | 01 Mar 2021 | 2,200 | 192,811 | - | 39.1 | 86,108 | Common Stock |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Jan 2021 | 41,514 | 166,051 | - | 0 | Common Stock | |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Jan 2021 | 41,514 | 198,811 | - | 0 | Common Stock | |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 28,000 | 194,051 | - | 0 | Common Stock | |
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | 03 Aug 2020 | 48,819 | 0 | - | - | Series B Convertible Preferred Stock | ||
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | 03 Aug 2020 | 32,759 | 32,759 | - | - | Common Stock | ||
Kalaris Therapeutics Inc. | Edward Miller | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2020 | 200,600 | 200,600 | - | - | Stock Option (Right to Buy) |